Naoero vs South Africa: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Naoero
66.0%
in 2025
South Africa
65.0%
in 2025
Naoero rank
138th
South Africa rank
140th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Naoero
- South Africa
How they compare
Naoero currently reports 66.0% against 65.0% in South Africa, a difference of 1.0%.
The two have swapped places 3 times across 18 shared years of data; in 2008 it was South Africa ahead.
Naoero ranks 138th and South Africa ranks 140th of 194 countries.
South Africa has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Naoero | South Africa | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 5.0% | 5.0% | South Africa |
| 2010s | 0.0% | 77.2% | 77.2% | South Africa |
| 2020s | 62.7% | 81.7% | 19.0% | South Africa |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Naoero or South Africa?
- Naoero, at 66.0% against 65.0% in South Africa as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Naoero and South Africa?
- 1.0%, with Naoero ahead.
- How many years of comparable data are there for Naoero and South Africa?
- 18 years are reported by both, from 2008 to 2025.
- How do Naoero and South Africa rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Naoero ranks 138th and South Africa ranks 140th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.